109 results
8-K
EX-10.1
BGNE
BeiGene Ltd
5 Jun 24
Departure of Directors or Certain Officers
4:35pm
, medical affairs, business development, strategy and operations) which are in the interests of the long-term growth of the Group. For the avoidance
8-K
EX-10.1
BGNE
BeiGene Ltd
20 Mar 24
Departure of Directors or Certain Officers
4:10pm
”) of BeiGene, Ltd. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high
8-K
EX-99.1
e1vi5r1gz
15 Mar 24
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
4:52pm
8-K
EX-99.1
d3viz3km0b0 qa608
9 Nov 23
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
4:08pm
8-K
EX-99.1
0ga3juk
2 Aug 23
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
6:13am
8-K
EX-99.2
m0l39hmmbwlbg1m9mpl
15 Jun 23
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
4:43pm
8-K
EX-99.1
jx1s6r 3nzk4
15 Jun 23
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
4:43pm
8-K
EX-10.1
0k2cdg b3
29 Mar 23
Other Events
4:03pm
8-K
EX-99.1
kslclmgu7vfk1kmv
22 Nov 22
Other Events
4:07pm